CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

J Duell, A Obr, Marinela Augustin (Co-author), J Endell, H Liu, S Geiger, IM Silverman, S Ambarkhane, A Rosenwald

Research output: Contribution to journalLetter to the editorpeer-review

14 Citations (Web of Science)
Original languageEnglish
JournalLEUKEMIA & LYMPHOMA
DOIs
Publication statusPublished - 2021

Keywords

  • T-CELL THERAPY
  • RESISTANCE
  • LEUKEMIA

Cite this